These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12560245)

  • 1. Thrombocytopenia following treatment with platelet glycoprotein IIb/IIIa inhibitors.
    Christopoulos CG
    Blood; 2003 Feb; 101(4):1655; author reply 1655. PubMed ID: 12560245
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
    Aster RH; Curtis BR; Bougie DW; Dunkley S; Greinacher A; Warkentin TE; Chong BH;
    J Thromb Haemost; 2006 Mar; 4(3):678-9. PubMed ID: 16460451
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.
    Bougie DW; Wilker PR; Wuitschick ED; Curtis BR; Malik M; Levine S; Lind RN; Pereira J; Aster RH
    Blood; 2002 Sep; 100(6):2071-6. PubMed ID: 12200368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
    Kleiman NS
    Coron Artery Dis; 1998; 9(9):603-16. PubMed ID: 9861523
    [No Abstract]   [Full Text] [Related]  

  • 7. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors.
    Abrams CS; Cines DB
    Curr Hematol Rep; 2004 Mar; 3(2):143-7. PubMed ID: 14965491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
    J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Mueller M; Lacock P; Anderson LC; Howard W; Blanck C; Schneider J; Abbottsmith CA
    J Thromb Thrombolysis; 2000 Feb; 9(2):149-55. PubMed ID: 10613996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
    Proimos G
    J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
    Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM
    J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M; Bertram U; Peter K; Bode C; Ruef J
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism.
    Gowda RM; Khan IA; Vasavada BC; Sacchi TJ
    Am J Ther; 2004; 11(4):302-7. PubMed ID: 15266223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IIb's are not IIb's.
    Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
    Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
    Lev EI; Osende JI; Richard MF; Robbins JA; Delfin JA; Rodriguez O; Sharma SK; Jayasundera T; Badimon JJ; Marmur JD
    J Am Coll Cardiol; 2001 Mar; 37(3):847-55. PubMed ID: 11693761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors.
    Weber AA; Meila D; Jacobs C; Weber S; Kelm M; Strauer BE; Zotz RB; Scharf RE; Schrör K
    Thromb Res; 2002 Apr; 106(1):25-9. PubMed ID: 12165285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.